EGFR and non-small cell lung carcinoma: This is the first prospective study demonstrating the feasibility of PNA clamping-assisted fluorescence melting curve analysis (PANAMutyperTM) of plasma ctDNA derived from NSCLC patients with activating and acquired resistant EGFR mutations.